RAGE, mitochondria, and tau pathology in AD
RAGE, mitochondria, and tau pathology in AD
批准号:
10532703
负责人:
SHI FANG YAN
金额:
$59.42万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-02-01 至 2024-11-30
关键词:
AffectAgeAlzheimer&aposs DiseaseAmyloid beta-ProteinAttenuatedAxonBiochemicalBioenergeticsBlood PlateletsBrainCell LineCell Surface ReceptorsCell surfaceChronicCognitiveComplexCytoplasmDataDefectDiseaseDisease ProgressionExhibitsFailureFunctional disorderHybridsImpaired cognitionImpairmentIn VitroInflammationInflammation MediatorsInflammatoryInflammatory ResponseInjuryKnockout MiceLearningLigandsLinkMAPT geneMediatingMemoryMemory impairmentMicrogliaMitochondriaMitochondrial DiseasesMorphologyMovementMusNeuronsOxidative StressPathogenesisPathologicPathologyPatientsPeripheralPlayProductionReactive Oxygen SpeciesRegulationResearchRespirationRoleSignal TransductionSiteStimulusStressStructureSynapsesTauopathiesTestingTissuesToxic effectTransducersTransgenic MiceTransgenic Organismsabeta accumulationage relatedcognitive functionfeasibility researchhuman modelimprovedin vivoinsightmitochondrial dysfunctionmutantneurofibrillary tangle formationneuroinflammationnovelreceptor expressionreceptor for advanced glycation endproductssynaptic functiontau Proteinstau aggregationtau mutationtau-1therapeutic targettraffickingtranscription factor
中文摘要
项目总结/摘要
线粒体和突触功能障碍是阿尔茨海默病(AD)的早期病理特征,
个脑袋生物能量学功能紊乱,呼吸衰竭,线粒体动力学异常,
在脑和外周组织中观察到活性氧(ROS)水平,
AD患者。晚期糖基化终产物受体(Receptor for Advanced Glycation Endproducts,AGEs)是一种
转导AGEs、S100/钙颗粒蛋白或淀粉样β肽(A β)的细胞表面受体位点。相互作用
β-淀粉样蛋白及其配体增加氧化应激、炎症、Aβ积聚,并损害突触功能
学习记忆。然而,研究表明,tau蛋白对tau蛋白和Aβ介导的线粒体应激的影响,
病理学方面,AD中tau诱导的突触和认知功能障碍仍不清楚。目前还不清楚是否以及如何
RAGE依赖的信号转导有助于AD中线粒体结构和功能的改变。
这项研究将验证这一假设,即线粒体膜电位作为信号转导的功能,扰乱线粒体
结构和功能以及氧化应激,导致突触线粒体和突触功能障碍。这
该提案将解决以下基本问题:在与广告相关的异常行为中,
线粒体和突触损伤,以及阻断线粒体和突触是否恢复线粒体和神经元功能。
英文摘要
PROJECT SUMMARY/ABSTRACT
Mitochondrial and synaptic dysfunction is early pathological features of the Alzheimer's disease (AD)-affected
brain. Perturbed bioenergetics function, respiration failure, aberrant mitochondrial dynamics, and increased
levels of reactive oxygen species (ROS) are observed in brains and peripheral tissues including platelets of
subjects with AD. RAGE (Receptor for Advanced Glycation Endproducts, AGEs) functions as a signal
transducing cell surface acceptor site for AGEs, S100/calgranuline, or amyloid-beta peptide (Aß). Interaction of
RAGE and its ligands increases oxidative stress, inflammation, Aβ accumulation, and impairs synaptic function
and learning memory. However, the impact of RAGE on tau- and Aβ-mediated mitochondrial stress, tau
pathology, tau-induced synaptic and cognitive dysfunction in AD remains unclear. It is unclear whether and how
RAGE-dependent signal transduction contributes to alterations in mitochondrial structure and function in AD.
The proposed studies will test the hypothesis that RAGE functions as signal transduction to perturb mitochondrial
structure and function, and oxidative stress, leading to synaptic mitochondrial and synaptic dysfunction. This
proposal will address the fundamental questions of whether RAGE is a key player in AD-related aberrant
mitochondria and synaptic injury and whether blockade of RAGE restores mitochondrial and neuronal function.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
RAGE, mitochondria, and tau pathology in AD
-
批准号:10320076
-
项目类别:
-
资助金额:$59.42万
-
财政年份:2019
-
负责人:SHI FANG YAN
-
依托单位:
PINK1 signaling and synaptic mitochondria integrity in AD
-
批准号:10091121
-
项目类别:
-
资助金额:$22.73万
-
财政年份:2018
-
负责人:SHI FANG YAN
-
依托单位:
Egr-1, PKC Beta, Signalling and Atherosclerosis
-
批准号:7162602
-
项目类别:
-
资助金额:$34.35万
-
财政年份:2005
-
负责人:SHI FANG YAN
-
依托单位:
Egr-1, PKC Beta, Signalling and Atherosclerosis
-
批准号:7330488
-
项目类别:
-
资助金额:$34.35万
-
财政年份:2005
-
负责人:SHI FANG YAN
-
依托单位:
Egr-1, PKC Beta, Signalling and Atherosclerosis
-
批准号:7006966
-
项目类别:
-
资助金额:$35.37万
-
财政年份:2005
-
负责人:SHI FANG YAN
-
依托单位:
Egr-1, PKC Beta, Signalling and Atherosclerosis
-
批准号:6867116
-
项目类别:
-
资助金额:$36.23万
-
财政年份:2005
-
负责人:SHI FANG YAN
-
依托单位:
Egr-1, PKC Beta, Signalling and Atherosclerosis
-
批准号:7568212
-
项目类别:
-
资助金额:$34.35万
-
财政年份:2005
-
负责人:SHI FANG YAN
-
依托单位:
Early Growth Response-1 (Egr-1), PKC Beta and Restenosis
-
批准号:7078584
-
项目类别:
-
资助金额:$31.93万
-
财政年份:2004
-
负责人:SHI FANG YAN
-
依托单位:
Early Growth Response-1 (Egr-1), PKC Beta and Restenosis
-
批准号:6894666
-
项目类别:
-
资助金额:$32.7万
-
财政年份:2004
-
负责人:SHI FANG YAN
-
依托单位:
Early Growth Response-1 (Egr-1), PKC Beta and Restenosis
-
批准号:6822517
-
项目类别:
-
资助金额:$32.7万
-
财政年份:2004
-
负责人:SHI FANG YAN
-
依托单位:
Early Growth Response-1 (Egr-1), PKC Beta and Restenosis
-
批准号:7234002
-
项目类别:
-
资助金额:$31.01万
-
财政年份:2004
-
负责人:SHI FANG YAN
-
依托单位:
Mouse Breeding and Procedure Core
-
批准号:8181500
-
项目类别:
-
资助金额:$31.98万
-
财政年份:--
-
负责人:SHI FANG YAN
-
依托单位:
AR & AGE-RAGE IN AGING: IMPACT ON ENDOTHELIAL AND VASCULAR STRESS
-
批准号:7796546
-
项目类别:
-
资助金额:$20.9万
-
财政年份:--
-
负责人:SHI FANG YAN
-
依托单位:
AR & AGE-RAGE IN AGING: IMPACT ON ENDOTHELIAL AND VASCULAR STRESS
-
批准号:8042640
-
项目类别:
-
资助金额:$21.31万
-
财政年份:--
-
负责人:SHI FANG YAN
-
依托单位:
Mouse Breeding and Procedure Core
-
批准号:8586333
-
项目类别:
-
资助金额:$32.92万
-
财政年份:--
-
负责人:SHI FANG YAN
-
依托单位:
TRANSGENIC MOUSE AND ANIMAL MANAGEMENT
-
批准号:8378067
-
项目类别:
-
资助金额:$52.42万
-
财政年份:--
-
负责人:SHI FANG YAN
-
依托单位:
RAGE and the host response to hypoxic stress
-
批准号:8378280
-
项目类别:
-
资助金额:$23.8万
-
财政年份:--
-
负责人:SHI FANG YAN
-
依托单位:
Mouse Breeding and Procedure Core
-
批准号:8976283
-
项目类别:
-
资助金额:$33.54万
-
财政年份:--
-
负责人:SHI FANG YAN
-
依托单位:
TRANSGENIC MOUSE AND ANIMAL MANAGEMENT
-
批准号:8235877
-
项目类别:
-
资助金额:$51.93万
-
财政年份:--
-
负责人:SHI FANG YAN
-
依托单位:
RAGE and the host response to hypoxic stress
-
批准号:8181491
-
项目类别:
-
资助金额:$23.92万
-
财政年份:--
-
负责人:SHI FANG YAN
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
芹菜素通过AGE-RAGE通路抑制干眼的炎症与氧化应激
-
批准号:82505677
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.00万元
-
批准年份:2025
-
负责人:吕雨霏
-
依托单位:
麝香通心滴丸通过干预AGE-RAGE轴调节O-GlcNAc修饰发挥防治DCM作用的药效物质及机制研究
-
批准号:82574874
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2025
-
负责人:刘天华
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位: